Does oncogenic K-ras activate p38 to maintain colorectal cancer cell proliferation during MEK inhibition?
Oncogenic K-ras activates p38alpha to maintain cell proliferation during MEK inhibition. MEK-targeting therapeutics can create an acquired tumor cell dependency on p38alpha.
RUDI is an effective and durable treatment of ISS and HF comparable with reported experiences with distal revascularization-interval ligation, proximalization of the arterial inflow, and banding. Patient selection is key for optimizing relief of symptoms and maintaining use of the access.